The association between the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor-1 gene and extension of postsurgical calf vein thrombosis.

Filippo Ferrara, Salvatore Novo, Giuseppina Novo, Valentina Cospite, Valentina Cospite, Francesco Meli, Filippo Ferrara, Salvatore Montalto, Salvatore Novo, Francesco Raimondi, Giuseppina Novo

Risultato della ricerca: Article

4 Citazioni (Scopus)

Abstract

The objective of this study was to evaluate whether the presence of a plasminogen activator inhibitor type 1 (PAI-1) promoter polymorphism 4G/5G could significantly influence the proximal extension of vein thrombosis in spite of anticoagulant treatment in patients with calf vein thrombosis (CVT) following orthopaedic, urological and abdominal surgery. We studied 168 patients with CVT, who had undergone orthopaedic, urological and abdominal surgery, subdivided as follows: first, 50 patients with thrombosis progression; second, 118 patients without thrombosis progression. The 4G/5G polymorphism of the plasminogen activator inhibitor 1 was evaluated in all patients and in 70 healthy matched controls. We also studied PAI-1 activity in plasma. The presence of 4G/5G genotype was significantly increased in the group of patients with the extension of thrombotic lesions and was associated with an increase in CVT extension risk (odds ratio adjusted for sex 2.692; 95% confidence interval 1.302-4.702). Moreover, we observed a significant increase of PAI-1 plasma activity in patients with extension of thrombotic lesion vs. patients without extension (P=0.0001). Patients with 4G/5G genotype in the promoter of the plasminogen activator inhibitor - 1 gene present a higher risk of extension of thrombotic lesions.
Lingua originaleEnglish
pagine (da-a)237-242
Numero di pagine6
RivistaBLOOD COAGULATION & FIBRINOLYSIS
Volume24
Stato di pubblicazionePublished - 2013

Fingerprint

Plasminogen Activator Inhibitor 1
Veins
Thrombosis
Genes
Orthopedics
Odds Ratio
Genotype
Anticoagulants
Confidence Intervals

All Science Journal Classification (ASJC) codes

  • Hematology

Cita questo

The association between the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor-1 gene and extension of postsurgical calf vein thrombosis. / Ferrara, Filippo; Novo, Salvatore; Novo, Giuseppina; Cospite, Valentina; Cospite, Valentina; Meli, Francesco; Ferrara, Filippo; Montalto, Salvatore; Novo, Salvatore; Raimondi, Francesco; Novo, Giuseppina.

In: BLOOD COAGULATION & FIBRINOLYSIS, Vol. 24, 2013, pag. 237-242.

Risultato della ricerca: Article

Ferrara, Filippo ; Novo, Salvatore ; Novo, Giuseppina ; Cospite, Valentina ; Cospite, Valentina ; Meli, Francesco ; Ferrara, Filippo ; Montalto, Salvatore ; Novo, Salvatore ; Raimondi, Francesco ; Novo, Giuseppina. / The association between the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor-1 gene and extension of postsurgical calf vein thrombosis. In: BLOOD COAGULATION & FIBRINOLYSIS. 2013 ; Vol. 24. pagg. 237-242.
@article{511fe8e39bb94b13b35b8be709be8adb,
title = "The association between the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor-1 gene and extension of postsurgical calf vein thrombosis.",
abstract = "The objective of this study was to evaluate whether the presence of a plasminogen activator inhibitor type 1 (PAI-1) promoter polymorphism 4G/5G could significantly influence the proximal extension of vein thrombosis in spite of anticoagulant treatment in patients with calf vein thrombosis (CVT) following orthopaedic, urological and abdominal surgery. We studied 168 patients with CVT, who had undergone orthopaedic, urological and abdominal surgery, subdivided as follows: first, 50 patients with thrombosis progression; second, 118 patients without thrombosis progression. The 4G/5G polymorphism of the plasminogen activator inhibitor 1 was evaluated in all patients and in 70 healthy matched controls. We also studied PAI-1 activity in plasma. The presence of 4G/5G genotype was significantly increased in the group of patients with the extension of thrombotic lesions and was associated with an increase in CVT extension risk (odds ratio adjusted for sex 2.692; 95{\%} confidence interval 1.302-4.702). Moreover, we observed a significant increase of PAI-1 plasma activity in patients with extension of thrombotic lesion vs. patients without extension (P=0.0001). Patients with 4G/5G genotype in the promoter of the plasminogen activator inhibitor - 1 gene present a higher risk of extension of thrombotic lesions.",
author = "Filippo Ferrara and Salvatore Novo and Giuseppina Novo and Valentina Cospite and Valentina Cospite and Francesco Meli and Filippo Ferrara and Salvatore Montalto and Salvatore Novo and Francesco Raimondi and Giuseppina Novo",
year = "2013",
language = "English",
volume = "24",
pages = "237--242",
journal = "Blood Coagulation and Fibrinolysis",
issn = "0957-5235",
publisher = "Lippincott Williams and Wilkins Ltd.",

}

TY - JOUR

T1 - The association between the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor-1 gene and extension of postsurgical calf vein thrombosis.

AU - Ferrara, Filippo

AU - Novo, Salvatore

AU - Novo, Giuseppina

AU - Cospite, Valentina

AU - Cospite, Valentina

AU - Meli, Francesco

AU - Ferrara, Filippo

AU - Montalto, Salvatore

AU - Novo, Salvatore

AU - Raimondi, Francesco

AU - Novo, Giuseppina

PY - 2013

Y1 - 2013

N2 - The objective of this study was to evaluate whether the presence of a plasminogen activator inhibitor type 1 (PAI-1) promoter polymorphism 4G/5G could significantly influence the proximal extension of vein thrombosis in spite of anticoagulant treatment in patients with calf vein thrombosis (CVT) following orthopaedic, urological and abdominal surgery. We studied 168 patients with CVT, who had undergone orthopaedic, urological and abdominal surgery, subdivided as follows: first, 50 patients with thrombosis progression; second, 118 patients without thrombosis progression. The 4G/5G polymorphism of the plasminogen activator inhibitor 1 was evaluated in all patients and in 70 healthy matched controls. We also studied PAI-1 activity in plasma. The presence of 4G/5G genotype was significantly increased in the group of patients with the extension of thrombotic lesions and was associated with an increase in CVT extension risk (odds ratio adjusted for sex 2.692; 95% confidence interval 1.302-4.702). Moreover, we observed a significant increase of PAI-1 plasma activity in patients with extension of thrombotic lesion vs. patients without extension (P=0.0001). Patients with 4G/5G genotype in the promoter of the plasminogen activator inhibitor - 1 gene present a higher risk of extension of thrombotic lesions.

AB - The objective of this study was to evaluate whether the presence of a plasminogen activator inhibitor type 1 (PAI-1) promoter polymorphism 4G/5G could significantly influence the proximal extension of vein thrombosis in spite of anticoagulant treatment in patients with calf vein thrombosis (CVT) following orthopaedic, urological and abdominal surgery. We studied 168 patients with CVT, who had undergone orthopaedic, urological and abdominal surgery, subdivided as follows: first, 50 patients with thrombosis progression; second, 118 patients without thrombosis progression. The 4G/5G polymorphism of the plasminogen activator inhibitor 1 was evaluated in all patients and in 70 healthy matched controls. We also studied PAI-1 activity in plasma. The presence of 4G/5G genotype was significantly increased in the group of patients with the extension of thrombotic lesions and was associated with an increase in CVT extension risk (odds ratio adjusted for sex 2.692; 95% confidence interval 1.302-4.702). Moreover, we observed a significant increase of PAI-1 plasma activity in patients with extension of thrombotic lesion vs. patients without extension (P=0.0001). Patients with 4G/5G genotype in the promoter of the plasminogen activator inhibitor - 1 gene present a higher risk of extension of thrombotic lesions.

UR - http://hdl.handle.net/10447/79645

M3 - Article

VL - 24

SP - 237

EP - 242

JO - Blood Coagulation and Fibrinolysis

JF - Blood Coagulation and Fibrinolysis

SN - 0957-5235

ER -